These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 11221291

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C, Romanet JP, Nordmann JP, Allaire C, Groupe d'étude.
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [Abstract] [Full Text] [Related]

  • 24. Barnidipine, a novel calcium antagonist for once-daily treatment of hypertension: a multicenter, double-blind, placebo-controlled, dose-ranging study. Dutch Barnidipine Multicenter Study Group.
    Hart W, Holwerda NJ.
    Cardiovasc Drugs Ther; 1997 Nov; 11(5):637-43. PubMed ID: 9493701
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.
    Papademetriou V.
    Am J Cardiol; 2009 Jan 15; 103(2):273-8. PubMed ID: 19121451
    [Abstract] [Full Text] [Related]

  • 27. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients.
    Johnson AG, Pearce GL, Danoff TM.
    J Hum Hypertens; 2006 Jul 15; 20(7):496-503. PubMed ID: 16543907
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
    Tytus RH, Burgess ED, Assouline L, Vanjaka A.
    Clin Ther; 2007 Feb 15; 29(2):305-15. PubMed ID: 17472822
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Hilleman DE, Reyes AP, Wurdeman RL, Faulkner M.
    J Hum Hypertens; 2001 Aug 15; 15(8):559-65. PubMed ID: 11494095
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M.
    Am J Hypertens; 2004 Jun 15; 17(6):495-501. PubMed ID: 15177521
    [Abstract] [Full Text] [Related]

  • 37. Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients.
    Böhm M, Ewald S, Olmebest Study Authors.
    Curr Med Res Opin; 2006 Jul 15; 22(7):1375-80. PubMed ID: 16834836
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan 15; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B, Khder Y.
    Clin Ther; 2005 Jul 15; 27(7):1013-21. PubMed ID: 16154480
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.